Characterization and regulation of the angiotensin II type-1 receptor (binding and mRNA) in human adrenal fasciculata-reticularis cells  by Naville, D. et al.
Volume 321, number 2,3, 184-188 FEBS 12345 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
April 1993 
Characterization and regulation of the angiotensin II type-l receptor 
(binding and mRNA) in human adrenal fasciculata-reticularis cells 
D. Naville”, M.C. Lebrethon”, A.Y. Kermabonb, E. Rouerb, R. Benarousb and J.M. Saeza 
“INSERM U307, H6pital Debrousse, 69322 Lyon Cedex 05, France and bICGM, INSERM U332, Paris, France 
Received 5March 1993 
The classical concept of human adrenal physiology indicates that only glomerulosa cells are the target of A-II. Herein, we demonstrated that cultured 
human adrenal fasciculata-reticularis cells were also responsive to this hormone. Indeed, these cells contained high affinity (Kd = 0.9-l. 1 nM) and 
low capacity (8,000-13,000 sites/cell) A-II receptors, and more than 95% of them were of the type-l. These AT1 receptors are functional since A-II 
was able to increase cortisol production after 48 h of treatment. These effects were inhibited by losartan, an AT1 antagonist, but not by CGP 42112A, 
an AT2 antagonist. The expression of the type-l A-II recptor mRNA was detected in the whole adrenal in both adult and fetus, and in cultured 
human adrenal fasciculata-reticularis cells. In these cells A-II negatively regulated AT1 receptor mRNA, and this effect was also mediated through 
the AT1 receptor subtype. 
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1. INTRODUCTION 
Angiotensin II (A-II) is a pleiotropic factor which 
exerts a variety of physiological responses in vascular 
and non-vascular tissues [l]. Multiple mechanisms of 
signal transduction have been shown to be involved in 
A-II actions, including phosphoinositide breakdown, 
mobilization of intracellular calcium, calcium channels 
and inhibition of adenylate cyclase activity [2,3]. 
coupled to intracellular effecters and are able to in- 
crease glucocorticoid production [ 16181. In contrast, it 
has been suggested that human adrenal fasciculata cells 
do not respond to A-II [19]. In this paper, we have 
attempted to study the A-II receptors in cultured human 
adrenal fasciculata cells and we have demonstrated that 
adult human adrenal fasciculata-reticularis cells contain 
functional AT1 receptors and corresponding mRNA 
which are negatively regulated by the hormone. 
Two pharmacologically distinct A-II receptor sub- 
types have been described so far by using specific antag- 
onists [4], but all the effects currently associated with 
A-II seem to be mediated by the A-II type-l (ATl) 
receptors. These receptors have high affinities for the 
non-peptide antagonist DuP 753/losartan [4,5]. The role 
of the AT2 receptors, which have high affinities for the 
peptide CGP 42112A and non-peptide PD 123 177 an- 
tagonists [6,7], is not well known. Recently, it has been 
suggested that A-II decreases the cellular concentration 
of cGMP in neurons through AT2 receptors [S], and 
Bottari et al. [9] have suggested that AT2 receptors 
could activate a membrane-associated phosphotyrosine 
phosphatase. A third type of A-II receptors (AT3) has 
been postulated [lo], but they are not yet well character- 
ized. The gene and/or cDNA encoding for the AT1 
receptor has been cloned in the rat [ 111, bovine [ 121 and, 
more recently, in the human [13-151. 
2. MATERIALS AND METHODS 
Synthetic angiotensin-II (A-II) was purchased from Bachem 
(Bubendorf, Switzerland); insulin, transferrin and bacitracin from 
Sigma (Saint-Louis, MO, USA), bovine serum albumin (BSA) from 
Boehringer (Meylan, France); nystatin from Gibco (Paris, France); 
penicillin/streptomycin, fetal calf serum and Dulbecco’s Modified 
Eagle’s Medium/Ham’s nutrient mixture F-12 (DMEM/FlZ 1:l) from 
J-Bio (Villejust, France). Specific antagonist DuP-753 or losartan was 
obtained from DuPont Merck (Wilmington, USA) and CGP42112A 
was a gift of Dr. de Gasparo (Ciba-Geigy, Base], Switzerland). 
2.1. Isolation, subcloning and expression of the human angiotensin-II 
type I receptor 
It has been shown that cultured bovine adrenal fascic- 
ulata cells contain high affinity A-II receptors which are 
Correspondence address: J.M. Saez, INSERM U 307, Hopital De- 
brousse, 29 Rue Soeur Bouvier, 69322 Lyon Cedex 05, France. Fax: 
(33) 78 25 61 68. 
A human liver ilgtll cDNA library (Clontech, Palo Alto, CA, USA) 
was screened using PCR methodology. The primers used were syn- 
thetic oligonucleotides specific for the itgtl 1 phage sequence and syn- 
thetic oligonucleotides specific for the published bovine AT1 receptor 
sequence [12] at first, or specific for the human sequence as soon as 
we determined it. PCR fragments obtained were sequenced by dideoxy 
chain termination [20] using [a-“S]dATP and Sequenase (US Bio- 
chemical Corp., Cleveland, OH, USA) according to the instructions 
provided and after subcloning in SmaI-cleaved ptZl8 (Pharmacia- 
France, St. Quentin en Yvelines). The nucleotide sequence for human 
AT1 receptor obtained was identical to that recently published [13]. 
We then subcloned a fragment containing the whole translated 
sequence of the human AT1 receptor into the EcoRIIEumHI-cleaved 
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eukaryotic expression vector pSGS (Stratagene, La Jolla, CA, USA), 
giving pSG5-hAT1. This fragment was recovered from the recombi- 
nant ptZl8 vector after cutting by the EcoRI and BarnHI enzymes. 
Studies of A-II binding were done after transfection of COS-7 cells 
using the DEAE-dextran method, as previously described [21]. 
2.2. Human adrenal cell isolation and culture 
Human adult adrenals were obtained after organ removal for trans- 
plantation from brain-dead patients, with the approval of the ethical 
committee of the Hospices Civils de Lyon. After having removed the 
major part of the medulla, the zona fasciculata-reticularis was sepa- 
rated from the capsula and used for cell preparation. Cells were dis- 
persed by two collagenase digestions (1 mg/ml) in DMEMIF-12 me- 
dium supplemented with NaHC03 (14 mM) and HEPES (10 mM) and 
containing gentamycin (20 @ml), penicillin (100 U/ml), streptomycin 
(0.1 m&ml) and nystatin (100 U/ml). Cells were then placed in mono- 
layer cultures in the same medium containing 2% fetal calf serum plus 
insulin (lO@ml), transferrin (lO,@ml) and vitamin C (10m4 M). After 
24 h, the medium was changed to the same medium without serum. 
Treatments were conducted in this defined medium starting on day 3 
of culture. 
2.3. Receptor binding assays 
A-II and the AT2 receptor antagonist CGP 42112A were labeled by 
the iodogen method [22]. The method used for [‘2SI]A-II purification 
has been described [22] and [“‘I]CGP 42112A was purified by HPLC 
on a Cl8 PBondapak column (Millipore, Guyancourt, France). The 
receptor assay was performed on COS-7 cells 6&65 h after transfec- 
tion with pSG5-hAT1, or at day 3 or 4 of culture for the human 
adrenocortical cells. According to the procedure described by Crozat 
et al. [16], biding was carried out in 0.5 ml FlZ-DME medium con- 
taining 0.1% bacitracin, 0.5% BSA and about 2 x lo5 cpm (0.2-0.3 
nM) of labeled A-II (or labeled CGP 42112A) for 1 h at 37°C. Non- 
specific binding was determined by the addition of 10d6 M unlabeled 
A-II (or unlabeled CGP 42112A). Competition experiments were per- 
formed in the presence of various concentrations of A-II, or in the 
presence of the specific antagonists losartan and CGP 42112A. At the 
end of the incubation, binding medium was removed and cells were 
washed 3 times with cold NaCl 0.9%. The cells were recovered after 
lysis with 0.4% deoxycholate in 0.5 M NaOH. 
2.4. RNA extraction and Northern blot analysis 
Total RNA was isolated from tissues or cells by the method of 
Chomczynski and Sacchi [23]. Then samples were separated by elec- 
trophoresis in a 1.0% agarose gel containing 8% formaldehyde. RNA 
was then transferred to a Hybond-N membrane (Amersham, Les Ulis, 
France). Prehybridization was performed in sodium citrate buffer 
(SSC 5 x) pH 7.0, containing 50% formamide, 1 x PE (5 x PE = 250 
mM Tris-HCl, pH 7.5; 0.5% sodium pyrophosphate; 5% SDS; 1% 
polyvinylpyrrolidone; 1% ficoll; 25 mM EDTA and 1% BSA), and 150 
&ml salmon sperm DNA at 42’C for 4 h. Hybridizations were 
performed in the same buffer at 42°C for 24 h, using a 918-bp frag- 
ment of the human AT1 receptor as a probe. Labeling of this probe 
in the presence of [u-32P]dCTP was performed with a Multiprime 
DNA labeling system (Amersham). The blots were washed 2 times in 
a 2 x SSC buffer containing 0.1% SDS at room temperature for 15 
min; one time in 0.2 x SSC containing 0.1% SDS at room temperature 
for 30 min, and finally in 0.2 x SSC plus 0.1% SDS at 55°C for 5-10 
min. Radioactivity was quantified by scanning densitometry using a 
Preference HIT (Sebia, Paris, France). 
3. RESULTS AND DISCUSSION 
Displacement of labeled A-II by unlabeled hormone 
was performed on cultured human adrenal fasciculata- 
reticularis cells (HAC) (Fig. 1). Scatchard analysis (Fig. 
1B) indicated the presence of 8,000 to 13,000 sites/cell, 
which represents alow number when compared to those 
found in bovine or ovine adrenocortical cells which 
have close to 100,000 sites per cell [ 16,241. The apparent 
Kd (0.9-1.1 nM) was found to be the same order of 
magnitude as that for ATI-transfected COS cells 
(2.9 k 1.6 nM) (Fig. 2), which is consistent with values 
obtained by other authors [ 13,141. The majority of A-II 
binding to HAC was displaced to 1.5 It: 2.2% of control 
by the addition of losartan (an AT1 specific ligand) at 
10m5 M (n = 7). When the binding assay was done in the 
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Fig. 1. (A) Displacement of [‘Z51]A-II bound to HAC by increasing concentrations of unlabeled A-II, of losartan in the presence of lo-’ M CGP 
42112A or of CGP 42112A in the presence of 10m6 M losartan. B (inset) shows the Scatchard plot of the binding data for A-II. 
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Fig. 2. (A) Displacement of [‘ZSI]A-II bound to COS-7 cells transfected with the human ATI receptor, as described in section 2, by increasing 
concentrations of unlabeled A-II, DuP 753 (losartan) or CGP 42112A (data represent he means of four different experiments). B (inset) shows 
the Scatchard plot of the binding data for A-II (Kd = 2.9 f 1.6 nM with about 135,000 sites/cell). 
presence of 5 x 10m8 M CGP 42112A (an AT2 specific 
ligand), the binding was only inhibited to 93.6 + 12.6% 
(n = 6) of the control. Th ese concentrations of losartan 
and CGP 42112A were chosen because they have been 
demonstrated to be saturating for the AT1 and AT2 
sites in bovine adrenocortical cells (BAC), respectively 
[18]. In COS cells transfected with pSG5-hAT1, which 
then expressed only the AT1 receptors, an almost com- 
plete displacement was obtained in the presence of 10e5 
M of losartan with an I&, of about 5 x lOWE M (Fig. 2). 
In contrast, CGP 42112A displaced bound A-II only at 
concentration higher than 10v7 M (Fig. 2) concentra- 
tion at which this compound recognizes AT1 receptor 
subtype. From these results it seems that only a very 
small part of the A-II receptors are of the AT2 subtype 
in HAC (less than 5%). This was confirmed by a second 
series of experiments where the displacement of labeled 
A-II by CGP 42112A was performed in the presence of 
1 2 3 4 5 6 7 
Fig. 3. 30 pg of total RNA from human testis (lane 1), human liver 
(lane 2), HepG2 cells (lane 3), human adult (lane 4) and fetal (lane 5) 
adrenal were used in the Northern blot analysis. Electrophoresis also 
included RNA from bovine liver (lane 6) and adrenal (lane 7). Blot was 
hybridized with the AT1 receptor probe as described in section 2. 
saturating concentrations of losartan (10e6 M), while 
that by losartan was performed in the presence of satu- 
rating concentrations of CGP 42112A (lo-’ M) (Fig. 
1A). Residual specific binding was about 5-6% in the 
presence of 10m6 M losartan with no further displace- 
ment by CGP 42112A, both in HAC cells (Fig. 1A) and 
in AT1 transfected COS cells (data not shown). 
The absence of AT2 receptor subtype in HAC was 
confirmed by binding studies using labeled CGP 
42112A. No specific binding could be demonstrated in 
either HAC or in AT1 transfected COS cells, when these 
cells were incubated in the presence of 2 x 10’ cpm of 
[‘251]CGP 42112. However, under similar experimental 
conditions BAC specifically bound about 20% of the 
total radioactivity, which was displaced by increasing 
concentrations of unlabeled CGP 42112A, but not by 
losartan (R. Ouali and J.M. Saez, unpublished results). 
Further evidence of the presence of AT1 receptor 
subtype in HAC was obtained by Northern blot analy- 
sis. In human tissues AT1 mRNA was expressed as a 
single transcript of 2.4 kb, while a single band of 3.3 kb 
was observed in bovine tissue (Fig. 3). In human the 
AT1 mRNA levels were higher in liver than in human 
or fetal adrenal, while in bovine the adrenal content was 
higher than the liver content. A single AT1 receptor 
mRNA transcript of 2.4 kb was also observed in HAC 
(Fig. 4). Treatment of HAC with A-II reduced in a 
time-dependent manner the amounts of AT1 mRNA, 
and this effect was abolished by losartan but not by 
CGP 42112A (Fig. 3). In contrast a four day treatment 
with ACTH did not significantly modify the AT1 recep- 
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Fig. 4. HAC cells were cultured for 96 h (A) or for the indicated time (B) in the presence of lo-’ M A-II with or without losartan (10e6 M) and/or 
10e8 M CGP. Electrophoresis was performed using 15 pg of total RNA and the AT1 receptor cDNA was used as a probe as described in section 2. 
tor mRNA levels (data not shown). The inhibitory ef- 
fects of A-II on AT1 receptor mRNA has also been 
observed in cultured rat glomerulosa mesangial cells 
[25] and in BAC (R. Ouali and J.M. Saez, unpublished 
results). 
Next, we investigated whether A-II was able to stim- 
ulate the specific function of HAC, namely the secretion 
of cortisol. Cells were incubated for 24 h without or with 
ACTH or A-II, and the amounts of cortisol and aldos- 
terone measured in the medium. ACTH produced a 
40-fold increase in cortisol secretion, whereas the effects 
of A-II were less pronounced (5-fold stimulation) (Table 
I). These effects of A-II were abolished by losartan, but 
not by the AT2 antagonist CGP 42112A. Moreover, 
both hormones stimulated about sixfold the secretion of 
aldosterone. However, the ratio cortisol/aldosterone in- 
dicated that the contamination of our preparation with 
glomerulosa cells was very small. In order to investigate 
the effects of the pretreatment on the steroidogenic re- 
sponsiveness, the cells were washed and then incubated 
2 h with either ACTH or A-II. In not pretreated cells, 
Table I 
both hormones enhanced cortisol production, but the 
effect of ACTH was higher than that of A-II. Pretreat- 
ment with ACTH increased the steroidogenic response 
to both hormones. This effect is probably related to the 
positive effect of the hormone on its own receptor [26] 
and on the expression of the genes encoding for the 
steroidogenic enzymes [27]. A-II also enhanced the cor- 
tisol secretion in response to further stimulation with 
either ACTH or A-II. Since long-term treatment of 
zona glomerulosa cells with A-II is unable to shift ster- 
oid biosynthesis from an aldosterone-producing to a 
cortisol-producing pathway [28], the most likely expla- 
nations for the above effects of A-II are its positive 
action on the expression of the ACTH receptor gene 
and on some of the genes encoding for the steroidogenic 
enzymes including cytochrome P-450 17a-hydroxylase 
(M.C. Lebrethon, D. Naville and J.M. Saez, submitted 
for publication). Moreover, the negative effect of A-II 
on its own receptors might explain that the responsive- 
ness to A-II of cells pretreated with this hormone was 
lower than that of ACTH pretreated cells (Table I). 
Pretreatment ng/mg of protein/24 h 
Cortisol Aldosterone 
Cortisol ng/2 h 
ACTH (1O-8 M) A-II (lo-’ M) 
None 
ACTH (1O-8 M) 
A-II (1O-7 M) 
A-II + DuP (10-h M) 
A-II + CGP (5 x 1O-8 M) 
4lf 2 0.10 2 0.01 PI? 5 18k 1 
1,971 f 114 0.63 k 0.1 452 f 25 166 + 9 
249 f 20 0.77 + 0.2 201 f 20 30 f 2 
78f 8 ND ND ND 
274 k 30 ND ND ND 
ND, not determined. 
Human adrenal fasciculata cells were incubated for 24 h in the presence or absence of the indicated hormones and the cortisol and aldosterone 
in the medium were measured. Then the cells were washed and incubated in fresh medium containing 10e8 M ACTH or lo-’ M A-II and after 
2 h the cortisol was measured in the medium. The results are means f S.D. of triplicate determinations of four different wells. 
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In conclusion, the present results demonstrate for the 
first time the presence of functional A-II receptors 
(mainly of the AT1 form) in human adrenal fasciculata- 
reticularis cells which allow an increase in the produc- 
tion of cortisol and that A-II negatively regulates AT1 
receptor mRNA through the AT1 receptors. 
WI Sasaki, K., Yamano, Y., Bardhan, S., Iwai, N., Murray, J.J., 
Hasagawa, M., Matsuda, Y. and Inagami, T. (1991) Nature 351, 
230-233. 
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